Abstract
Meldonium is an anti-ischemia drug developed in 1970 by Ivars Kalvins at the USSR Latvia Institute of organic synthesis. Meldonium is reportedly capable of providing clinical benefit for those suffering from heart conditions, such as low blood flow to the heart and angina, as well as neurodegenerative disorders and bronchopulmonary diseases. It appears that the medical utility of meldonium derives mostly from its ability to modulate cellular energy metabolism1. This may be due to the drug lowering the consumption of fatty acids, while increasing utilization of carbohydrates for the production of energy. In short, meldonium is advertised as an energy-efficiency catalyst. Since 1 January 2016, it has been on the World Anti-Doping Agency (WADA) list of substances banned from use by athletes. In this work a screening and a confirmation method for Meldonium from urine were developed and validated on LC-MS/MS triple quadrupole (liquid chromatography coupled with mass spectrometry ) (ABSciex QTrap 5500). The validation parameters evaluated were limit of detection, matrix effects, identification criteria, specificity, carry-over and extraction recovery. The evaluated parameters are in accordance with WADA technical documents, both methods being applicable for doping control application.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
